Cimpress N.V. - Investor Relations - Investor Relations

Vistaprint Investor Relations

OVERVIEW

The domain ir.vistaprint.com presently has a traffic classification of zero (the smaller the more traffic).

IR.VISTAPRINT.COM TRAFFIC

The domain ir.vistaprint.com is seeing variant amounts of traffic until the end of the year.
Traffic for ir.vistaprint.com

Date Range

1 week
1 month
3 months
This Year
Last Year
All time
Traffic ranking (by month) for ir.vistaprint.com

Date Range

All time
This Year
Last Year
Traffic ranking by day of the week for ir.vistaprint.com

Date Range

All time
This Year
Last Year
Last Month

LINKS TO IR.VISTAPRINT.COM

WHAT DOES IR.VISTAPRINT.COM LOOK LIKE?

Desktop Screenshot of ir.vistaprint.com Mobile Screenshot of ir.vistaprint.com Tablet Screenshot of ir.vistaprint.com

IR.VISTAPRINT.COM SERVER

We caught that a lone root page on ir.vistaprint.com took zero milliseconds to stream. Our web crawlers could not discover a SSL certificate, so our parsers consider this site not secure.
Load time
0 sec
SSL
NOT SECURE
IP
184.51.0.249

FAVICON

SITE TITLE

Cimpress N.V. - Investor Relations - Investor Relations

DESCRIPTION

Vistaprint Investor Relations

PARSED CONTENT

The domain had the following in the site, "Nasdaq CMPR is the world leader in mass customization." I observed that the web page stated " For 20 years, the company has focused on developing software and manufacturing capabilities that transform traditional markets in order to make customized products accessible and affordable to everyone." They also stated " Cimpress NV Investor Day 2015. Cimpress NV Fourth Quarter Fiscal Year 2015 Earnings Live QA session. Cimpress Q4 Fiscal Year 2015 Earnings Press Release." The meta header had Vistaprint Investor Relations as the first keyword.

SEE OTHER WEB PAGES

Investor Relations VIVUS, Inc.

With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. We are a focused organization with the expertise and insights to advance innovative new therapies. VIVUS Reports Fourth Quarter 2017 Financial Results.